American College Of Surgeons - Inspiring Quality: Highest Standards, Better Outcomes

Return to Screening PDSA and Clinical Study: August Screening Numbers and Interventions

Commission on Cancer (CoC)- and National Accreditation Program for Breast Centers (NAPBC)-accredited programs participating in the Return to Screening Plan/Do/Study/Act (PDSA) and Clinical Study are reminded to please record their post-intervention monthly screening rates for August 2021. Programs are required to monitor and record monthly screening rates from April 1, 2021, and continue through November 30, 2021.

Programs only participating in the PDSA will input this information on the writeable forms located online within the Return to Screening page.

Programs participating in the clinical study should continue to enter their information through REDCap. The REDCap form B/C can be opened and edited at any time before the final submission using the “Save and Return Later” button at the bottom of the form.

We have received several questions regarding updates to form A in REDCap and issues with access to form B/C. For assistance, please e-mail Jessica Dangles and include the following information: name and e-mail of the individual who completed the form (this may be different from your PI) and the disease site.

Skin Cancer Sessions at This Year’s Clinical Congress

Clinical Congress is virtual this year! If you are looking to learn more about skin cancer, both melanoma and non-melanoma, we have two sessions for you.

On Monday, October 25, Panel Session PS332, Update on the Care of the Non-Melanoma Skin Cancer Patient, starts at 11:00 am CT. This 60-minute session reviews new advances in multidisciplinary management treatment of non-melanoma skin cancer, including basal cell carcinoma, squamous cell and Merkel cell carcinomas, and dermatofibrosarcoma protuberans. The session will also address hedgehog inhibitors, surgical margins, utility of sentinel lymph node biopsy, systemic hedgehog inhibitors for basal cell carcinoma, and new approved immunotherapy options for squamous cell and Merkel cell carcinoma. This session will be moderated by Jonathan S. Zager, MD, FACS, and co-moderated by Jeffrey M. Farma, MD, FACS.

On Wednesday, October 27, Panel Session PS561, The Changing Paradigm in Melanoma Treatment: Incorporating Neoadjuvant Immunotherapy and Targeted Therapy, starts at 2:00 pm CT. With the explosion of both immunotherapy and targeted therapy in the treatment of melanoma, there is rapidly emerging data regarding effective incorporation of neoadjuvant approaches in the treatment of locally advanced disease. There are also a number of national trials investigating this very question with which the audience should be familiar. Nasreen A. Vohra, MD, FACS, will moderate and Bruce M. Brenner, MD, FACS, will co-moderate.

For more information on all of the cancer offerings at Clinical Congress, please visit this web page.